Pressmeddelande -
We welcome Camilla Jidling - our new QA Manager
Scandinavian Biopharma continues to expand and strengthen its quality organization. Camilla Jidling has been hired as the new Quality Assurance Manager and has been working at Scandinavian Biopharma since the beginning of the summer.
Camilla most recently worked at OxThera, where she, as Senior QA / QC Manager, coordinated the company's analytical activities, was responsible for stability studies and analysis method transfers and was also responsible for the implementation of the company's electronic documentation system and the development of the organization's quality system. Prior to that, Camilla worked as a QA at Cobra Biologics and she also has a background as a laboratory engineer at Crucell and Sobi.
- It feels very exciting to be part of the team that will develop the world's first vaccine against ETEC diarrhoea. I hope that my previous experience of the quality requirements that apply to clinical studies can contribute to further developing Scandinavian Biopharma's quality system, says Camilla Jidling.
- Camilla's solid industry experience from quality work suits Scandinavian Biopharma perfectly and she is a very valuable addition as we continue our growth journey, says Björn Sjöstrand, CEO Scandinavian Biopharma.
Ämnen
Kategorier
About Scandinavian Biopharma
Scandinavian Biopharma is a research-based specialty biopharma company determined to give people all over the world a longer and better life. Together with researchers at the University of Gothenburg and the international non-profit organization PATH, Scandinavian Biopharma is developing the first vaccine against ETEC which causes diarrhoea in both travellers and endemic populations.
The development project is mainly funded by the EDCTP programme, which is supported under Horizon 2020, the European Union’s (EU) Framework Programme for Research and Innovation, as well as by PATH and the U.S. Army (USAMMDA).
Scandinavian Biopharma also acts as a distributor for a wide range of specialty biopharma products in Europe with a focus on vaccines and immunoglobulins.
About ETEC
Enterotoxigenic Escherichia coli, or ETEC, is a major cause of bacterial diarrhoeal disease. ETEC infections are particularly common in low- and middle-income countries (LMIC). In children younger than 5 years, it has been estimated that 1.7 billion episodes of diarrhoea occur annually. ETEC represents a major cause of these episodes and accounts for approximately 400 000 deaths among children living in LMICs. In addition, diarrhoea is associated with an increased risk of stunting (i.e. impaired growth and development). Stunting affects cognitive development which might determine a child’s ability to learn, their educational attainment, and future earnings and it also puts children at risk due to other severe infectious diseases.
ETEC is also the leading cause of travellers’ diarrhoea, affecting more than 35 million travellers every year.
About ETVAX®
To date, no vaccine against ETEC exists and ETVAX® is the only ETEC vaccine candidate in late-stage development. The strong immunogenicity and safety data, as well as the promising field efficacy data, clearly distinguish ETVAX® as the lead vaccine candidate against ETEC. Successful development of this vaccine will address a huge unmet medical need for children in LMICs as well as for travellers.
